Axsome Therapeutics, Inc. announced the completion of patient enrollment in the GEMINI study, a Phase 3, randomized, double-blind, placebo-controlled trial of AXS-05 in patients with major depressive disorder AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.
October 16, 2019
· 7 min read